Science & Medicine

ASH 2014: SNAPSHOT: Morgan Lam and Imetelstat

i,etelstat abstract

Conclusions: The current study identifies imetelstat as an active drug in patients with MF, but also reveals its potential to cause significant myelosuppression. The association between CR/PR and specific mutations suggests potential targeted activity that might be exploited for patient and disease selection.’– Dr. Ayalew Tefferi  from ASH abstract

634 Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

Morgan Lam, Geron Director, Clinical Operations, Imetelstat

Morgan Lam, Geron Project DIrector, Imetelstat






Take me back to the Contents

©  2014, MPNforum, LLC and Zhenya Senyak. Unauthorized use and/or duplication of this material without express and written permission is prohibited. Excerpts and links may be used, provided that full and clear credit is given to with appropriate and specific direction to the original content. All rights reserved under Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: